Testing RAG-17 for ALS with SOD1 gene mutation
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a new drug, RAG-17, for people with ALS who have a specific SOD1 gene mutation. The goal is to see if it's safe and how it affects the body, which may help slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ALS and a SOD1 gene mutation (but not the p.F21C type).
- You are 18 years or older.
- Your breathing test (FVC) is at least 50% of the healthy average for your age, sex, and height.
- If you take riluzole or edaravone, you've been on a steady dose for at least 30 days before starting.
- You haven't had any other experimental drug, stem cell therapy, or gene therapy recently.
- You are not pregnant or breastfeeding and have no major infections like HIV or hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment aimed at restoring the function of a gene called UNC13A in people with ALS. It involves multiple clinic visits, MRI scans, and spinal taps to see if the treatment is safe and may slow the disease.
This study tests a new medicine called BIIB147 to see if it is safe and to learn how it affects people with ALS. It may help slow the progression of the disease.
This trial tests RAPA-501, a treatment made using your own immune cells, to slow progression of ALS. It may help by changing how your immune system responds in ALS.
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
This trial tests a single injection of a gene therapy called INS1202 into the spinal fluid. It is for people with ALS, including those with a specific genetic form (SOD1 mutation). The goal is to see if it is safe and how it affects the body.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.